Literature DB >> 2610504

Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits.

J W Lee1, C Lin, D Loebenberg, M Rubin, P A Pizzo, T J Walsh.   

Abstract

We studied the plasma pharmacokinetics and tissue penetration of Sch 39304 (SCH), a new antifungal triazole, in granulocytopenic [G(+)] and nongranulocytopenic [G(-)] rabbits. Five female New Zealand White G(-) rabbits were given a single oral dose of 2 mg of SCH per kg of body weight. Levels in plasma, determined by gas-liquid chromatography-electron capture, were obtained for 6 days. This procedure was repeated 2 weeks later with the same rabbits, which were induced and maintained G(+) with cytosine arabinoside. There were no significant differences between the pharmacokinetic parameters of G(+) and G(-) rabbits. Among all animals studied, the maximum concentration of the drug in plasma was 1.4 +/- 0.11 micrograms/ml at 4 +/- 0.5 h, the half-life was 25 +/- 1.4 h, the volume of distribution at steady state was 3.8 +/- 0.3 liters, and the area under the concentration-time curve was 44 +/- 3.4 micrograms.h/ml. SCH was detectable in plasma up to day 6. Levels of SCH in tissue were studied at steady state in six G(+) and six G(-) rabbits receiving 2 mg of the drug orally per kg per day for experimental disseminated candidiasis. Tissue SCH levels equalled or exceeded those in plasma (at steady state) at all sites examined, and these ratios were similar in both G(+) and G(-) rabbits. Thus, plasma pharmacokinetics of orally administered SCH were similar for G(+) and G(-) rabbits, and SCH achieved high levels of penetration into multiple tissues, including the liver and the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2610504      PMCID: PMC172790          DOI: 10.1128/AAC.33.11.1932

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.

Authors:  T J Walsh; J Bacher; P A Pizzo
Journal:  Lab Anim Sci       Date:  1988-08

2.  Noncompartmental determination of the steady-state volume of distribution for any mode of administration.

Authors:  D Perrier; M Mayersohn
Journal:  J Pharm Sci       Date:  1982-03       Impact factor: 3.534

Review 3.  Treatment of systemic fungal infections: recent progress and current problems.

Authors:  T J Walsh; A Pizzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

4.  Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients.

Authors:  I M Hann; H G Prentice; R Corringham; H A Blacklock; M Keaney; M Shannon; P Noone; E Gascoigne; J Fox; E Boesen; M Szawatkowski; A V Hoffbrand
Journal:  Lancet       Date:  1982-04-10       Impact factor: 79.321

Review 5.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

  5 in total
  10 in total

1.  Systemic antifungal agents.

Authors:  L O Gentry
Journal:  Tex Heart Inst J       Date:  1990

2.  Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates.

Authors:  T J Walsh; C Lester-McCully; M G Rinaldi; J E Wallace; F M Balis; J W Lee; P A Pizzo; D G Poplack
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration.

Authors:  P Mojaverian; E Radwanski; M B Affrime; M N Cayen; C C Lin
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

4.  Pharmacokinetics and metabolism of genaconazole, a potent antifungal drug, in men.

Authors:  C Lin; H Kim; E Radwanski; M Affrime; M Brannan; M N Cayen
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits.

Authors:  T J Walsh; J W Lee; J Lecciones; P Kelly; J Peter; V Thomas; J Bacher; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

6.  In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent.

Authors:  T Tanio; K Ichise; T Nakajima; T Okuda
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Treatment of murine coccidioidal meningitis with SCH39304.

Authors:  J Defaveri; S H Sun; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 8.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

9.  Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.

Authors:  T F Patterson; D George; R Ingersoll; P Miniter; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

10.  Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing.

Authors:  T C Hardin; P K Sharkey; Y F Lam; J E Wallace; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.